Form Type: 4

SEC EDGAR Link
Accession Number:0001012975-20-000291
Date:2020-03-04
Issuer: AKERO THERAPEUTICS, INC. (AKRO)
Original Submission Date:

Reporting Person:

VENBIO GLOBAL STRATEGIC FUND II L.P.
1700 OWENS STREET, SUITE 595
SAN FRANCISCO, CA 94158

Reporting Person:

VENBIO GLOBAL STRATEGIC GP II, L.P.
1700 OWENS STREET, SUITE 595
SAN FRANCISCO, CA 94158

Reporting Person:

VENBIO GLOBAL STRATEGIC GP II, LTD.
1700 OWENS STREET, SUITE 595
SAN FRANCISCO, CA 94158

Reporting Person:

ADELMAN ROBERT J
1700 OWENS STREET, SUITE 595
SAN FRANCISCO, CA 94158

Reporting Person:

GOODMAN COREY S
1700 OWENS STREET, SUITE 595
SAN FRANCISCO, CA 94158

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-03-04 S 35,650 d $23.81 3,160,319 indirect f4
COMMON STOCK 2020-03-05 S 8,500 d $23.53 3,151,819 indirect f4
COMMON STOCK 2020-03-06 S 1,800 d $23.79 3,150,019 indirect f4
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $22.86 to $24.12, inclusive. the reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
f2 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $23.00 to $23.92, inclusive. the reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $23.41 to $24.00, inclusive. the reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
f4 these shares are held by venbio global strategic fund ii, l.p. venbio global strategic gp ii, lp is the sole general partner of venbio global strategic fund ii, lp and venbio global strategic gp ii, ltd. is the sole general partner of venbio global strategic gp ii, l.p. robert adelman and corey goodman are directors of venbio global strategic gp ii, ltd. each of venbio global strategic gp ii, l.p., venbio global strategic gp ii, ltd., mr. adelman and mr. goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.
WhaleWisdom Logo

Elevate your investments